Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02651688 · ClinicalTrials.gov registry record · Phase 2
A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene
A Phase 2 study of Obesity and Acquired Hypogonadotropic Hypogonadism, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 5
- Study locations
NCT02651688 is a Phase 2 study of Obesity and Acquired Hypogonadotropic Hypogonadism that has completed, run by Repros Therapeutics. The registered enrollment target is 50 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT02651688, a Phase 2 study of Obesity and Acquired Hypogonadotropic Hypogonadism, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic hypogonadism \[confirmed morning testosterone (T) ≤300 ng/dL\] following a 6 month diet and 15 month exercise program.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Enclomiphene
Study Locations (5)
New York
- - Albany
- - Garden City
Rhode Island
- - Providence
Utah
- - Riverton
Virginia
- - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-01-11 |
| Est. Completion | 2017-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02651688
The ClinicalTrials.gov registry entry for NCT02651688 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower). The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02651688 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, Rhode Island, Utah.
Frequently Asked Questions
What is clinical trial NCT02651688 about?
NCT02651688 is a clinical study titled "A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene". The purpose of this study is to compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic hypogonadism \[confirmed morning testosterone (T) ≤300 ng/dL\] following a...
What is the current status of trial NCT02651688?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2016-01-11. Estimated completion is 2017-05-02.
What conditions does trial NCT02651688 study?
This clinical trial studies the following conditions: Obesity, Acquired Hypogonadotropic Hypogonadism.
What interventions are being tested in trial NCT02651688?
The interventions under investigation include: Placebo (DRUG), Enclomiphene (DRUG).
Who is sponsoring clinical trial NCT02651688?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02651688 being conducted?
This trial has 5 study locations across New York, Rhode Island, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.